Genetic Signatures’ FluA assay
A newly emerging variant of Influenza A (FluA) H3N2, referred to as Subclade K, formerly J.2.4.1, has been increasing in prevalence in the Northern Hemisphere since mid-2025. 1, 2 In-silico alignment confirms that our EasyScreen™ Respiratory Pathogen Detection Kit (RP007) will efficiently detect all currently known sequences of the FluA H3N2 Subclade K variant. Our…
Read MoreA year of transformation and impact
Allison Rossiter reflects on her first year as CEO at Genetic Signatures Just over a year ago, Allison Rossiter stepped into the role of CEO at Genetic Signatures, leaving behind the structure and scale of Roche to lead a smaller, purpose-driven organisation. It was a bold move, and one that would both challenge, and inspire…
Read MoreGenetic Signatures Confirms Reliable Detection of Emerging COVID-19 Variant, NB.1.8.1
Genetic Signatures SARS-CoV-2 Detection Kit detects recent SARS-CoV-2 Omicron variant NB.1.8.1. As Australia moves into the winter season, local health authorities are urging communities to receive booster COVID-19 vaccinations, particularly for more vulnerable populations, as a rise in COVID-19 cases is anticipated in the coming weeks. This urgency has been fuelled by the recent detection…
Read MoreLaboratories urged to plan ahead as Australia anticipates another record-breaking respiratory season
An elevated prevalence of influenza cases and emerging pockets of Respiratory Syncytial Virus (RSV) activity have epidemiologists concerned for a record-breaking respiratory season in Australia. The added health risks of increased transmission of other leading respiratory infections, in addition to the potential increase in the prevalence of co-infection, may increase the prevalence of coinfections and…
Read MoreGenetic Signatures Announces Strategic Channel Partnership with Almog Diagnostic for Market Entry into Israel
Sydney, 29th August 2023: Genetic Signatures, a leading innovator in molecular diagnostics, is pleased to announce a strategic channel partnership with Almog Diagnostic, facilitating our entry into the Israeli market. This exclusive partnership further enhances Genetic Signatures’ footprint in the Middle East, extending access to our patented 3base® technology and syndromic solutions for infectious diseases…
Read MoreGenetic Signatures Announces Strategic Partnership with Integrated Gulf Biosystems for Expanded Market Reach in the Middle East
Sydney, 22nd August, 2023: Genetic Signatures, a leading innovator in molecular diagnostics, is pleased to announce a new channel partner in the Middle East, Integrated Gulf Biosystems (IGB). With IGB’s headquarters in Dubai, the exclusive agreement allows Genetic Signatures to tap into the promising market of United Arab Emirates, Kingdom of Saudi Arabia, Bahrain and…
Read MoreWorld Antimicrobial Awareness Week 2022: Preventing Antimicrobial Resistance Together
Spread Awareness, Stop Resistance World Antimicrobial Awareness Week Antimicrobial resistance (AMR) Priority pathogens Integrated stewardship: Collaboration with clinical laboratories to optimise antimicrobial therapy Genetic Signatures 3-base™ EasyScreen™ Detection Kit for AMR testing Evaluation Studies World Antimicrobial Awareness Week The World Health Organisation (WHO) has declared antimicrobial resistance (AMR) as one the most challenging…
Read MoreA trusted partnership to support reliable, high throughput PCR testing for COVID-19 in Germany
KH Labor GmbH is an independent company within the AMEOS group of hospitals, providing laboratory diagnostic services across 8 different sites in Germany. KH Labor offers a large spectrum of services to support hospital inpatient and outpatient testing, and COVID-19 testing for public health departments and agencies, and testing centres. The company’s mission is to…
Read MoreOmicron BA.4 and BA.5 Subvariants
Contents Epidemiology Healthcare Burden and Public Health Response 3base™ Technology Confident Detection of All Known SARS-CoV-2 Variants with 3base™ Customer Experience with the EasyScreen™ SARS-CoV-2 Detection Kit (RP012) Contact your local team References Summary Omicron BA.4 and BA.5 subvariants now represent over half of all COVID-19 infections globally, due to new mutations enhancing viral transmission…
Read More3base Technology and Reliable Detection of SARS-CoV-2 Variants
Genetic Signatures announces the launch of their multiplex real-time SARS-CoV-2 Variant Detection Kit, which can specifically identify Omicron (B.1.1.529) and other key SARS-CoV-2 variants. Summary Genetic Signatures announces the development of their SARS-CoV-2 Variant Detection Kit, which can specifically identify the Omicron (B.1.1.529), Delta and Beta variants by detecting specific mutations, and includes a…
Read More